Home > Press > AMAG Pharmaceuticals, Inc. to Present at Two Upcoming Healthcare Conferences
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO of AMAG Pharmaceuticals, Inc. will present an overview of the Company at the Bear Stearns 20th Annual Healthcare Conference at 9:00 a.m. ET on Tuesday, September 11, 2007. The conference is being held at the Grand Hyatt Hotel in New York.
AMAG Pharmaceuticals, Inc. to Present at Two Upcoming Healthcare Conferences
CAMBRIDGE, MA | Posted on September 5th, 2007
Dr. Pereira will also present a corporate overview at the UBS Global Life Sciences Conference at 1:30 p.m. ET on Wednesday, September 26, 2007. This conference is also being held at the Grand Hyatt Hotel in New York.
Live audio webcasts of these presentations will be accessible through the Investors section of the company's web site at http://www.amagpharma.com . Following the conferences, the audio webcasts will be archived on the AMAG Pharmaceuticals, Inc. web site until October 27, 2007.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
Ferumoxytol, the Company’s lead product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in chronic kidney disease patients.
Combidex®, the Company’s other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with MRI to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the Company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.
For more information, please click here
AMAG Pharmaceuticals, Inc.
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
MANA Research Highlight: Smart nanofibers to treat kidney failure March 6th, 2014
Harris & Harris Group, Inc. Establishes and Invests $350,001 in ProMuc, Inc. March 6th, 2014
First Look at How Individual Staphylococcus Cells Adhere to Nanostructures Could Lead to New Ways to Thwart Infections: Berkeley Lab-led research could guide the development of bacteria-resistant materials March 5th, 2014
Dartmouth Researchers Find Promising Results with Local Hyperthermia of Tumors March 4th, 2014
Squeezing light into metals: University of Utah engineers control conductivity with inkjet printer March 7th, 2014
Up-Converted Radio: The way to treat radio waves in a noisy environment is to turn them into visible light March 7th, 2014
New Data Model Boosts Space Science March 6th, 2014
Carbodeon NanoDiamonds PTFE Coating doubles surface durability and reduces friction by up to 66 percent: New surface coating enables cost-effective CO2 and fuel reductions in machinery March 6th, 2014
Singapore's A*STAR IME will present 9 papers in optical device innovation and foundry-qualified platform development at world-class optical communications conference March 6th, 2014
How 19th Century Physics Could Change the Future of Nanotechnology: University of Cincinnati physics researchers have developed a new way of using an old technique that could help build better nanotechnology March 5th, 2014
Malvern Instruments announces guest presenter for March 18th protein characterization webinar: Renowned protein scientist Prof. Dr. John F. Carpenter shows how combining Dynamic Light Scattering with Raman Spectroscopy delivers new insights in protein stability, aggregation... March 4th, 2014
UC research tests which nano system works best in killing cancer cells: New UC research to be presented this week tested four iron-oxide nanoparticle systems to see which, when heated, would likely work best as a tool for targeting cancer cells March 4th, 2014